INDIVIDUALIZATION OF PHENYTOIN THERAPYLUDDEN TM.1980; J. PHARM. PHARMACOL.; GBR; DA. 1980; VOL. 32; NO 2; PP. 152; BIBL. 9 REF.Article

N-ACETYLPROCAINAMIDE KINETICS AFTER SINGLE AND REPEATED ORAL DOSESLUDDEN TM; CRAWFORD MH.1982; CLIN. PHARMACOL. THER.; ISSN 0009-9236; USA; DA. 1982; VOL. 31; NO 3; PP. 343-349; BIBL. 22 REF.Article

THE BIOAVAILABILITY, DISPOSITION KINETICS AND DOSAGE OF SULPHADIMETHOXINE IN DOGS.BAGGOT JD; LUDDEN TM; POWERS TE et al.1976; REV. CANAD. MED. COMP.; CANADA; DA. 1976; VOL. 40; NO 3; PP. 310-317; ABS. FR.; BIBL. 16 REF.Article

RAPID ESTABLISHMENT OF THERAPEUTIC SERUM CONCENTRATIONS OF SALICYLATESTALBERT RL; LUDDEN TM; WEST RE et al.1979; J. CLIN. PHARMACOL.; USA; DA. 1979; VOL. 19; NO 2-3; PP. 108-112; BIBL. 22 REF.Article

CONTINUOUS INFUSION OF LIDOCAINE IN PATIENTS WITH CARDIAC ARRHYTHMIAS: UNPREDICTABILITY OF PLASMA CONCENTRATIONSSAWYER DR; LUDDEN TM; CRAWFORD MH et al.1981; ARCH. INTERN. MED. (1960); ISSN 0003-9926; USA; DA. 1981; VOL. 141; NO 1; PP. 43-45; BIBL. 18 REF.Article

DEVELOPMENT OF A LOADING REGIMEN FOR ASPIRINTALBERT RL; LUDDEN TM; LITTLEFIELD LC et al.1980; CURR. THERAPEUT. RES.; USA; DA. 1980; VOL. 27; NO 4; PP. 584-594; BIBL. 37 REF.Article

DETERMINATION OF HYDRALAZINE IN HUMAN WHOLE BLOODLUDDEN TM; LUDDEN LK; WADE KE et al.1983; JOURNAL OF PHARMACEUTICAL SCIENCES; ISSN 0022-3549; USA; DA. 1983; VOL. 72; NO 6; PP. 693-695; BIBL. 12 REF.Article

RAPID METABOLISM OF PHENYTOIN. A METHOD OF CALCULATING PROPER DOSAGEHAWKINS DW; LUDDEN TM; HOFFMAN SF et al.1979; ARCH. NEUROL.; USA; DA. 1979; VOL. 36; NO 2; PP. 109-110; BIBL. 10 REF.Article

ELIMINATION OF RADIOACTIVITY FOLLOWING ADMINISTRATION OF (15,16-³H) NALTREXONE TO RATS AND GUINEA PIGSLUDDEN TM; BATHALA MS; MALSPEIS L et al.1978; DRUG METABOL. DISPOSIT.; USA; DA. 1978; VOL. 6; NO 3; PP. 321-328; BIBL. 19 REF.Article

FACTORS INFLUENCING PROCAINAMIDE TOTAL BODY CLEARANCE IN THE IMMEDIATE POSTMYOCARDIAL INFARCTION PERIODWYMAN MG; GOLDREYER BN; CANNOM DS et al.1981; J. CLIN. PHARMACOL.; ISSN 0091-2700; USA; DA. 1981; VOL. 21; NO 1; PP. 20-25; BIBL. 13 REF.Article

PHENYTOIN CUMULATION KINETICSALLEN JP; LUDDEN TM; BURROW SR et al.1979; CLIN. PHARMACOL. THERAPEUT.; USA; DA. 1979; VOL. 26; NO 4; PP. 445-448; BIBL. 23 REF.Article

CLINICAL PHARMACOKINETICS OF HYDRALAZINELUDDEN TM; MCNAY JL JR; SHEPHERD AMM et al.1982; CLIN. PHARMACOKINET.; ISSN 0312-5963; AUS; DA. 1982; VOL. 7; NO 3; PP. 185-205; BIBL. 4 P.Article

SIMULTANEOUS DETERMINATION OF CHLORAMPHENICOL AND CHLORAMPHENICOL SUCCINATE IN PLASMA USING HIGH-PERFORMANCE LIQUID CHROMATOGRAPHYVELAGAPUDI R; SMITH RV; LUDDEN TM et al.1982; J. CHROMATOGR.; ISSN 0021-9673; NLD; DA. 1982; VOL. 228; PP. 423-428; BIBL. 16 REF.Article

THE PRODUCTION OF FREE FATTY ACIDS IN POST-HEPARIN PLASMA DURING EQUILIBRIUM DIALYSISHAMILTON SF; WALLER ES; YAKATAN GJ et al.1982; RES. COMMUN. CHEM. PATHOL. PHARMACOL.; ISSN 0034-5164; USA; DA. 1982; VOL. 35; NO 3; PP. 519-522; BIBL. 7 REF.Article

HYDRALAZINE KINETICS AFTER SINGLE AND REPEATED ORAL DOSESSHEPHERD AMM; LUDDEN TM; MCNAY JL et al.1980; CLIN. PHARMACOL. THER.; ISSN 0009-9236; USA; DA. 1980; VOL. 28; NO 6; PP. 804-811; BIBL. 30 REF.Article

HYDRALAZINE KINETICS IN HYPERTENSIVE PATIENTS AFTER INTRAVENOUS ADMINISTRATIONLUDDEN TM; SHEPHERD AMM; MCNAY JL et al.1980; CLIN. PHARMACOL. THER.; ISSN 0009-9236; USA; DA. 1980; VOL. 28; NO 6; PP. 736-742; BIBL. 21 REF.Article

RATE OF PHENYTOIN ACCUMULATION IN MAN: A SIMULATION STUDYLUDDEN TM; ALLEN JP; SCHNEIDER LW et al.1978; J. PHARMACOKINET. BIOPHARMACEUT.; GBR; DA. 1978; VOL. 6; NO 5; PP. 399-415; BIBL. 28 REF.Article

MICRODETERMINATION OF PROCAINAMIDE IN HUMAN SERUM.LUDDEN TM; LALKA D; WYMAN MG et al.1978; J. PHARM. SCI.; U.S.A.; DA. 1978; VOL. 67; NO 3; PP. 371-373; BIBL. 16 REF.Article

METABOLIC REDUCTION OF NALTREXONE. I. SYNTHESIS, SEPARATION AND CHARACTERIZATION OF NALOXONE AND NALTREXONE REDUCTION PRODUCTS AND QUALITATIVE ASSAY OF URINE AND BILE FOLLOWING ADMINISTRATION OF NALTREXONE, ALPHA -NALTREXOL, OR BETA -NALTREXOL. = REDUCTION METABOLIQUE DE LA NALTREXONE. I. SYNTHESE, SEPARATION ET CARACTERISATION DES PRODUITS DE REDUCTION DE LA NALOXONE ET DE LA NALTREXONE ET ANALYSE QUALITATIVE DE L'URINE ET DE LA BILE APRES ADMINISTRATION DE NALTREXONE, ALPHA -NALTREXOL OU BETA -NALTREXOLMALSPEIS L; BATHALA MS; LUDDEN TM et al.1975; RES. COMMUNIC. CHEM. PATHOL. PHARMACOL.; U.S.A.; DA. 1975; VOL. 12; NO 1; PP. 43-65; BIBL. 2 P.Article

HEMODYNAMIC EFFECTS OF N-ACETYLPROCAINAMIDE IN HEART DISEASECRAWFORD MH; LUDDEN TM; KENNEDY GT et al.1982; CLIN. PHARMACOL. THER.; ISSN 0009-9236; USA; DA. 1982; VOL. 31; NO 4; PP. 459-465; BIBL. 19 REF.Article

METABOLIC REDUCTION OF NALTREXONE. II. IN VITRO STUDIES USING LIVER FROM GUINEA PIG, MONKEY AND RAT.MALSPEIS L; LUDDEN TM; BATHALA MS et al.1976; RES. COMMUNIC. CHEM. PATHOL. PHARMACOL.; U.S.A.; DA. 1976; VOL. 14; NO 3; PP. 393-406; BIBL. 1 P. 1/2Article

IMPROVED ASSAYS FOR HYDRALAZINE AND HYDRALAZINE PYRUVIC ACID HYDRAZONE IN HUMAN PLASMALUDDEN TM; LUDDEN LK; MCNAY JL et al.1980; ANAL. CHIM. ACTA; ISSN 0003-2670; NLD; DA. 1980; VOL. 120; NO 1; PP. 297-304; BIBL. 17 REF.Article

TRITIATED NALTREXONE BINDING IN PLASMA FROM SEVERAL SPECIES AND TISSUE DISTRIBUTION IN MICE = LA FIXATION DE NALTREXONE TRITIEE DANS LE PLASMA DE PLUSIEURS ESPECES ET LA REPARTITION TISSULAIRE CHEZ LES SOURISLUDDEN TM; MALSPEIS L; BAGGOT JD et al.1976; J. PHARM. SCI.; U.S.A.; DA. 1976; VOL. 65; NO 5; PP. 712-716; BIBL. 25 REF.Article

INITIAL EXPERIENCE OF CLINICAL PHARMACOLOGY AND CLINICAL PHARMACY INTERACTIONS IN A CLINICAL PHARMACOKINETICS CONSULTATION SERVICETAYLOR JW; MCLEAN AJ; LEONARD RG et al.1979; J. CLIN. PHARMACOL.; USA; DA. 1979; VOL. 19; NO 1; PP. 1-7; BIBL. 24 REF.Article